LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
Rhea-AI Summary
Lunai Bioworks (NASDAQ:LNAI) CEO outlined progress in biodefense, precision neurology, and shareholder protections. The company secured its first revenue-generating, multi-year U.S. defense contract via BioSymetrics for AI-enabled chemical threat assessment and formed the Pathfinder Consortium with leading universities.
Lunai is advancing its Augusta™ AI neurology platform in epilepsy, Parkinson’s, and Alzheimer’s, including a BrainStorm collaboration and a Phase I/II NIH STTR grant of $1.85 million. The company initiated litigation over alleged naked short selling, is in expedited discovery, and reports renewed compliance with NASDAQ listing requirements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- First revenue-generating multi-year U.S. defense contract via BioSymetrics
- Formation of Pathfinder Consortium with multiple leading research institutions
- Augusta AI neurology programs in epilepsy, Parkinson’s, and Alzheimer’s advancing
- NIH Phase I/II STTR grant of $1.85 million awarded to BioSymetrics
- Legal action and expedited discovery aimed at addressing alleged naked short selling
- Company reports restored compliance with NASDAQ listing requirements
Negative
- Company reports trading activity not reflecting operational and partnership progress
- Alleged anomalous failing-to-deliver of 29.6 million shares (81.6% of float)
- Peak daily trading volume cited at 554 million shares, 15.3x outstanding shares
- Ongoing litigation may entail costs and uncertainty for Lunai and shareholders
News Market Reaction – LNAI
On the day this news was published, LNAI gained 40.60%, reflecting a significant positive market reaction. Argus tracked a peak move of +30.4% during that session. Argus tracked a trough of -42.0% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $5M to the company's valuation, bringing the market cap to $18.14M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | AI neurology deal | Positive | +16.0% | Foundation-funded AI neurology collaboration with BrainStorm Therapeutics and organoid models. |
| May 22 | Litigation update | Neutral | -2.6% | Federal judge orders expedited discovery in naked short-selling case against John Doe traders. |
| May 20 | Reverse stock split | Negative | -2.6% | Company implements 1-for-8 reverse split to address Nasdaq minimum bid-price requirements. |
| May 4 | Preferred financing, IP | Positive | +1.5% | Completes $20M preferred issuance to acquire CNS delivery and neurotherapeutic IP assets. |
| Apr 15 | Rare disease LOI | Positive | -4.7% | Subsidiary signs LOI with Geneial to build rare neurological disease patient cohorts. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with clear strategic or AI/neurology focus often coincided with positive moves, while structural or trading-related items drew mixed to negative reactions.
Over the past few months, Lunai Bioworks has announced multiple AI-driven neurology and biodefense initiatives, including a BrainStorm Therapeutics collaboration on May 28, 2026 and an IP acquisition via a $20.0M preferred issuance on May 1, 2026. Structural actions like the 1-for-8 reverse split on May 22, 2026 and rare-disease LOI on April 15, 2026 produced muted or negative reactions. Today’s CEO letter ties together biodefense, neurology, and litigation themes already visible in this sequence of prior announcements.
Regulatory & Risk Context
Key Terms
naked short selling financial
in vivo medical
synthetic dna medical
nucleic acid synthesis medical
biodefense medical
phase i/ii medical
nasdaq listing requirements regulatory
contingent ai technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Fellow Shareholders,
Over the past several months, Lunai Bioworks (NASDAQ: LNAI) has continued to execute its strategy of building a next-generation biotechnology company at the intersection of artificial intelligence, and national security and biology. I would like to update you on developments that have substantially strengthened our position and created multiple pathways for shareholder value creation.
A RARE STRATEGIC POSITION: THE NATIONAL SECURITY BIODEFENSE PLATFORM
In April 2026, we secured our first revenue-generating, multi-year defense collaboration through BioSymetrics to deploy our AI-enabled platform for chemical threat assessment. This contract represents not a research relationship but an active commercial engagement with the
Beyond that initial contract, we have established the Pathfinder Consortium—a national alliance of leading institutions including Harvard University, Brigham and Women's Hospital (led by Dr. Calum MacRae), the University of
Looking forward to the second half of 2026 we believe our Augusta platform which combines Contingent AI, large toxicity databases, and in vivo testing aligns with the priorities outlined in the 2027 Defense Authorization Bill published this month. It specifically calls for the nation "to develop a strategy to leverage artificial intelligence-enabled and high-throughput biological screening approaches in support of identifying and characterizing potential chemical neurotoxic threat agents". This is precisely what we are doing under our current contract and further involves the capabilities we now have with the Pathfinder Consortium.
PRECISION NEUROLOGY: A COMPLEMENTARY GROWTH ENGINE
In parallel, Lunai continues to advance its precision neurology pipeline through our Augusta™ AI platform in Epilepsy, Parkinsons, and Alzheimer's. We recently announced and are advancing collaborations including a partnership with BrainStorm Therapeutics supported by foundation funding, and we continue to benefit from NIH-supported research initiatives, including a Phase I/II STTR grant (
Neurological diseases remain among the most challenging and costly medical conditions, affecting millions of patients worldwide. By combining large-scale patient datasets with advanced AI analytics and validated with in vivo testing, we are identifying therapeutic opportunities that conventional methods miss. This work represents a significant long-term value driver for Lunai, and one that is independent of our biodefense activities.
THE CONVERGENCE: AI, BIOTECHNOLOGY, AND THE FULL SPECTRUM OF BIOLOGICAL THREATS
The strategic importance of biodefense is increasingly recognized by governments, scientists, and technology leaders worldwide.
Recently, the chief executives of Anthropic, OpenAI, Google DeepMind, and Microsoft AI, alongside numerous leaders from biotechnology and national security organizations, signed a public letter supporting enhanced safeguards around synthetic DNA and nucleic acid synthesis technologies. The letter highlights a fundamental concern: advances in artificial intelligence are rapidly reducing barriers to the design and engineering of biological agents.
This is not theoretical. The risks are dual: engineered biological threats from state and non-state actors, and the accelerating risk of novel pandemics—whether natural or human-engineered. The line between public health preparedness and national security has blurred entirely. COVID demonstrated the global health and economic cost of a biological event. The prospect of deliberate bioweapon creation through synthetic biology represents an equally grave but far less recognized threat.
Governments are responding. The recognition that the next biological crisis—pandemic or weaponized—could originate from either natural evolution or deliberate engineering is driving substantial investment in detection, identification, and countermeasure development at speeds and scales previously reserved for kinetic warfare.
Lunai's current biodefense activities focus on chemical threat assessment through our first revenue-generating defense contract and the Pathfinder Consortium. However, our AI-driven platform for threat identification, phenotypic screening, and countermeasure discovery is directly applicable across the full spectrum of biological threats—both pandemic and weaponized. We are actively exploring partnerships and opportunities to expand our biodefense capabilities into biological threat detection and countermeasure development. Given the government's growing recognition of both pandemic and bioweapon risks, and our existing partnerships with leading scientific institutions and federal agencies, we believe we are well-positioned to participate in what will become a major national security and public health priority.
PROTECTING SHAREHOLDER VALUE: LITIGATION AS VALUE UNLOCK
As we continue to execute and announce meaningful milestones, we have observed trading activity that does not reflect the progress being achieved by Lunai.
In May 2026, we initiated legal action in the
Critically, the Court found good cause for expedited discovery and established a prima facie basis for our claims. This rule permits us to obtain trading records from broker-dealers, custodians, and market participants to identify those responsible. We are now in the discovery process.
The purpose of this litigation is straightforward: identify the parties engaged in improper market activity, hold them accountable, and restore shareholder value that has been artificially suppressed. Litigation discovery will force disclosure of positions, trading records, and brokerage relationships that shorts depend on keeping hidden. As those identities emerge, regulatory scrutiny of the short positions themselves becomes inevitable—and expensive to maintain.
We intend to pursue this matter vigorously. In our view, protecting shareholder interests and pursuing accountability for market manipulation is not a distraction, it is a core responsibility of management.
LOOKING FORWARD
Lunai today is substantially different from the company it was a year ago. We have established the first revenue-generating defense contract, assembled a national network of world-class scientific and military partners, continued to validate our AI-driven approach in both biodefense and precision neurology, and initiated legal action to address market manipulation artificially suppressing our stock price.
The convergence of AI, biotechnology, and national security is creating a rare strategic opportunity. Through our biodefense platform and precision neurology pipeline, we are building a company positioned to address some of the largest and most important markets, backed by government partners and validated by leading scientific institutions.
As we move through the second half of 2026, our focus remains clear: advancing and expanding our biodefense platform, neurology programs, executing our litigation strategy, and continuing to validate our platform across both healthcare and national security applications. Now that the company has achieved compliance with the NASDAQ listing requirements we are positioned to build long term value for our shareholders.
I would like to thank you for your continued support.
Sincerely,
David Weinstein
Chief Executive Officer
Lunai Bioworks, Inc.
View original content:https://www.prnewswire.com/news-releases/lunai-bioworks-ceo-letter-to-shareholders-302803131.html
SOURCE Lunai Bioworks Inc.